Orna Therapeutics Unveils Novel In Vivo Gene Editing Data Highlighting Engineering and Delivery Approach at the 31st Annual European Society of Gene & Cell Therapy Congress
--Lead type V editor program in SCD demonstrates industry leading delivery and repeat dosing with a passive LNP--